journal article·2024-09-13

Microfluidic Synthesis of Quaternary Chitosan Coated Liposome to Enhance Cellular Uptake and In Vivo Immune Responses

Chuan-Chang Chuang, Cheng-Cheung Chen, Xin-An Chen, Yu-Hsiu Chang, Chia-Ying Chin, Jenn-Jong Young, Chuan-Chung Chuang

ACS Applied Nano Materials· Volume 7· Issue 17
Publisher page

Abstract

This study relates to positively surface-charged liposomes ((+)-LPS) coated with cationic polyelectrolytes via covalent bonds and the preparation method and applications thereof. This nanosized (+)-LPS was synthesized via a single-step microfluidic process, in which the formation of LPS and the coating of N-[(2-hydroxy-3-trimethylammonium)propylchitosan (HTCC) on the surface via covalent bonds were completed in situ. Flow cytometric endocytosis analysis of (+)-LPS on JAWS II dendritic cells demonstrated that HTCC coated via covalent bonds showed higher uptake efficiency than those coated via hydrogen bonds and increased uptake by 100-fold compared to LPS without HTCC coating. HTCC-coated LPS, via covalent binding, also reduced the cytotoxicity after incubation with JAWS II cells. In vivo experiments showed that BALB/c mice vaccinated with anthrax vaccine adsorbed (AVA) mixed with HTCC-covalently coated (+)-LPS could induce IgG anti-PA antibodies in a shorter time and at a higher level than mice vaccinated with AVA plus (+)-LPS coated with HTCC via hydrogen bonds and AVA only and that the humoral immune response was more dominant. Moreover, the preparation process allows rapid and high-quality production of (+)-LPS with low cost and simple operation. Thus, the present disclosure is competitive with practicability, providing an advantage in commercialization.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Preventive Medicine, National Defense Medical Center, New Taipei City 23742, Taiwan, ROC

Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei City 11490, Taiwan, ROC

Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei City 11490, Taiwan, ROC

School of Dentistry and Graduate Institute of Dental Science, National Defense Medical Center, Taipei City 11490, Taiwan, ROC

Department of Dentistry, Tri-Service General Hospital, Taipei City 11490, Taiwan, ROC

Funding

Medical Affairs Bureau · Tri-Service General Hospital · National Defense Medical Center · National Science and Technology Council

References (56)

Show source-provided references
1. 10.2147/IJN.S6886110.2147/IJN.S68861 ↗
2. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
3. 10.1016/j.heliyon.2022.e0939410.1016/j.heliyon.2022.e09394 ↗
4. 10.1016/j.addr.2021.11385110.1016/j.addr.2021.113851 ↗
5. 10.1021/acs.chemrev.5b0004610.1021/acs.chemrev.5b00046 ↗
6. 10.1016/j.jconrel.2010.02.02110.1016/j.jconrel.2010.02.021 ↗
7. Immordino M. L. · Int. J. Nanomed. · 2006 · 1 · 297
8. 10.1007/s13346-015-0220-810.1007/s13346-015-0220-8 ↗
9. 10.1111/j.1750-3841.2008.00747.x10.1111/j.1750-3841.2008.00747.x ↗
10. 10.1016/j.ijpharm.2010.09.02810.1016/j.ijpharm.2010.09.028 ↗
11. 10.1016/S0169-409X(99)00041-110.1016/S0169-409X(99)00041-1 ↗
12. 10.1038/srep2587610.1038/srep25876 ↗
13. 10.1016/j.colsurfa.2020.12467010.1016/j.colsurfa.2020.124670 ↗
14. 10.3390/pr903044510.3390/pr9030445 ↗
15. 10.1016/j.ijpharm.2022.12227710.1016/j.ijpharm.2022.122277 ↗
16. 10.3390/molecules2402025010.3390/molecules24020250 ↗
17. 10.3390/nano1005082310.3390/nano10050823 ↗
18. 10.1016/j.colsurfb.2016.04.01010.1016/j.colsurfb.2016.04.010 ↗
19. 10.3390/ijms2118661710.3390/ijms21186617 ↗
20. 10.1039/C4TB00876F10.1039/C4TB00876F ↗
21. 10.1039/C5TB01517K10.1039/C5TB01517K ↗
22. 10.3390/md906103810.3390/md9061038 ↗
23. 10.1016/j.vaccine.2006.11.03410.1016/j.vaccine.2006.11.034 ↗
24. 10.1016/j.vaccine.2015.07.10110.1016/j.vaccine.2015.07.101 ↗
25. 10.3390/molecules2302022910.3390/molecules23020229 ↗
26. 10.3389/fimmu.2018.0056210.3389/fimmu.2018.00562 ↗
27. 10.1016/j.carbpol.2019.11540310.1016/j.carbpol.2019.115403 ↗
28. 10.1007/BF0015268610.1007/BF00152686 ↗
29. 10.1016/S0264-410X(01)00387-510.1016/S0264-410X(01)00387-5 ↗
30. 10.1016/S0264-410X(02)00723-510.1016/S0264-410X(02)00723-5 ↗
31. 10.1016/j.vascn.2015.02.00110.1016/j.vascn.2015.02.001 ↗
32. 10.1016/j.carbpol.2020.11604110.1016/j.carbpol.2020.116041 ↗
33. 10.1016/j.colsurfb.2024.11403010.1016/j.colsurfb.2024.114030 ↗
34. 10.1155/2011/72724110.1155/2011/727241 ↗
35. 10.1023/A:102055831716210.1023/A:1020558317162 ↗
36. 10.3389/fimmu.2020.0151310.3389/fimmu.2020.01513 ↗
37. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
38. 10.2147/IJN.S2659210.2147/IJN.S26592 ↗
39. 10.1016/j.ijpharm.2023.12340710.1016/j.ijpharm.2023.123407 ↗
40. 10.1007/s10965-011-9755-710.1007/s10965-011-9755-7 ↗
41. 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M ↗
42. 10.1073/pnas.93.4.162410.1073/pnas.93.4.1624 ↗
43. 10.3748/wjg.14.217410.3748/wjg.14.2174 ↗
44. 10.1038/s41577-019-0131-x10.1038/s41577-019-0131-x ↗
45. 10.1016/j.cytogfr.2007.10.00410.1016/j.cytogfr.2007.10.004 ↗
46. 10.1016/j.cytogfr.2007.10.00310.1016/j.cytogfr.2007.10.003 ↗
47. 10.4049/jimmunol.166.7.431210.4049/jimmunol.166.7.4312 ↗
48. 10.1002/eji.183027052610.1002/eji.1830270526 ↗
49. 10.4049/jimmunol.166.7.444610.4049/jimmunol.166.7.4446 ↗
50. 10.1016/j.imlet.2004.05.00310.1016/j.imlet.2004.05.003 ↗
51. 10.1182/blood-2006-05-01535410.1182/blood-2006-05-015354 ↗
52. 10.1371/journal.pone.023703410.1371/journal.pone.0237034 ↗
53. 10.1073/pnas.21142359810.1073/pnas.211423598 ↗
54. 10.1371/journal.pone.009939610.1371/journal.pone.0099396 ↗
55. 10.1146/annurev.iy.07.040189.00104510.1146/annurev.iy.07.040189.001045 ↗
56. 10.1016/j.exppara.2012.09.00110.1016/j.exppara.2012.09.001 ↗